Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using real-world experience in over 150,000 patients Compounded GLP-1 program ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

Medscape Medical News, June 25, 2024 ADA 2024 GLP-1 Kidney Benefits Seen With or Without SGLT2 Inhibitors Larger studies are needed because of the low numbers of patients on SGLT2 inhibitors in ...

New York, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from ...

and at ADA the drugmaker also reported mid-stage results with its oral candidate orforglipron, a non-peptide GLP-1 agonist. The study – published in the New England Journal of Medicine ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented ...

Taking a GLP-1 Medication? Here's Tips to Holiday Eating By Robin Foster HealthDay Reporter SATURDAY, Nov. 23, 2024 (HealthDay News) -- So, you have managed to shed 30 pounds with the help of one ...

Study Finds GLP-1 Meds Can Also Help the Kidneys By Ernie Mundell HealthDay Reporter TUESDAY, Nov. 26, 2024 (HealthDay News) -- The potential health benefits of GLP-1 diabetes and weight loss meds ...

Earlier at ADA, Lilly reported phase 2 results with its once-daily oral GLP-1 agonist orforglipron, which achieved a weight reduction of almost 15% at 24 weeks, potentially giving Lilly the option ...